0001193125-26-218156
SEC filingOperating losses deepened as Olema accelerated R&D investment in late-stage palazestrant trials, with net loss rising to $53.1 million.
Operating loss for the first quarter of 2026 was $58.0 million, compared to $34.9 million in the same period last year, a 66% increase. This widening loss reflects the company's intensified investment in its late-stage clinical programs, particularly the Phase 3 trials OPERA-01 and OPERA-02 for palazestrant. Research and development expenses rose significantly as the company advanced these pivotal studies. The net loss for the quarter was $53.1 million, or $0.52 per diluted share, compared to a net loss of $30.4 million, or $0.36 per diluted share, in the prior year period.
Since inception, Olema has not generated any revenue from product sales and has incurred significant operating losses and negative cash flows from operations. The company has funded its operations primarily through equity offerings and debt financing. The company expects to continue to incur net operating losses for at least the next several years as it advances its product candidates through clinical development.